Lunch & Learn: Strategies for Protecting Biomarker Innovation in the US and Abroad
Recent decisions by the US Supreme Court have found both isolated DNA and methods of assessing drug treatment efficacy by measuring metabolite levels are not eligible for patent protection. From these decisions, it’s become clear that the hard work of identifying a gene, or set of genes, which are correlated with a disease state is not enough to receive patent protection in the US. In contrast, isolated DNA is eligible for patent protection in many jurisdictions outside the US, such as Europe.
Moving forward, companies will likely consider innovation protection strategies which include some mix of patent and trade secret protection.
- Insight regarding the impact of these decisions and strategies for protecting biomarker innovation in the US and abroad
- Understanding which biomarker innovations are patent-eligible in the US and abroad
- Information enabling companies to craft a global innovation and protection strategy
BayBio Lunch & Learn:
February 19, 2014
HCP/BayBio Event Center
|Click Here to Register|
|Attire:||Business Attire Suggested|
- Early registration is highly advised as space is limited and there will be no on-site registration
- Late arrivals will not be admitted after 11:30AM
- Pre-registered attendees will receive an immediate receipt/confirmation after submission
- Please print this receipt/confirmation and bring it with you to receive your conference credentials
- Photo ID (driver’s license or passport) will be required at check-in
- All sales are final
Please mail your event-related questions to: email@example.com or you can contact us via phone: 650-871-3257.